Introduction European valvular heart disease guidelines define women as a ‘special group’. To explore what factors have led ...

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...

The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...

Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the ...

Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...

PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

LONDON, England—Ever since the 5-year PARTNER 3 and 4-year EVOLUT Low Risk results were released at TCT 2023, clinicians and researchers—not to mention industry players and ad execs—have been ...

Percutaneous heart valve specialist JenaValve Technology (Munich) just received $10 million in VC funding, supplementing the $62.5 million in funds the company won last year. The cash could help the ...